North America Whole Exome Sequencing Market – Industry Trends and Forecast to 2030

Request for TOC Request for TOC Speak to Analyst Speak to Analyst Buy Now Buy Now Inquire Before Buying Inquire Before Free Sample Report Free Sample Report

North America Whole Exome Sequencing Market – Industry Trends and Forecast to 2030

  • Medical Devices
  • Published Report
  • Sep 2023
  • North America
  • 350 Pages
  • No of Tables: 44
  • No of Figures: 38

North America Whole Exome Sequencing Market

Market Size in USD Billion

CAGR :  % Diagram

Diagram Forecast Period
2023 –2030
Diagram Market Size (Base Year)
USD 435.97 Million
Diagram Market Size (Forecast Year)
USD 2,192.73 Million
Diagram CAGR
%
Diagram Major Markets Players
  • Dummy1
  • Dummy2
  • Dummy3
  • Dummy4
  • Dummy5

North America Whole Exome Sequencing Market, By Component (Whole Exome Sequencing, Second-Generation Sequencing, and Third-Generation Sequencing), Product and Services (Systems, Kits and Services), Application (Diagnostics, Drug Discovery and Development, Personalized Medicine, Agriculture & Animal Research, and Others), End User (Hospitals & Clinics, Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, Clinical Laboratories, and Others), Distribution Channel (Direct Trade, Retail Sales, and Others) - Industry Trends and Forecast to 2030.

North America Whole Exome Sequencing Market

North America Whole Exome Sequencing Market Analysis and Insights

Increasing the preference of WES over whole-genome sequencing due to its low-cost sequencing capability are the major factors for drive the market growth in the forecast period. However, high instrument costs, the need for skilled professionals, and high reliance on grants and funds may hamper the future growth of whole exome sequencing market. Adoption of strategic alliances like partnerships and acquisitions by key market players act as opportunity for the growth of whole exome sequencing market.

Whole Exome Sequencing Market

Whole Exome Sequencing Market

Whole exome sequencing market is expected to gain market growth in the forecast period of 2023 to 2030. Data Bridge Market Research analyses that the market is growing with a CAGR of 22.0% in the forecast period of 2023 to 2030 and is expected to reach USD 2,192.73 million by 2030 from USD 435.97 million in 2022.

Report Metric

Details

Forecast Period

2023 to 2030

Base Year

2022

Historic Years

2021 (Customized to 2015-2020)

Quantitative Units

Revenue in USD Millions, Volumes in Units, Pricing in USD

Segments Covered

Component (Whole Exome Sequencing, Second-Generation Sequencing, and Third-Generation Sequencing), Product and Services (Systems, Kits and Services), Application (Diagnostics, Drug Discovery and Development, Personalized Medicine, Agriculture & Animal Research, and Others), End User (Hospitals & Clinics, Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, Clinical Laboratories, and Others), Distribution Channel (Direct Trade, Retail Sales, and Others)

Countries Covered

 U.S., Canada, and Mexico

Market Players Covered

Thermo Fisher Scientific Inc., QIAGEN, Illumina, Inc., Beckman Coulter, Inc., Eurofins Scientific, BIONEER CORPORATION, ExoDx (a part of Bio-Techne), FOUNDATION MEDICINE, INC. (A subsidiary of F. Hoffmann-La Roche Ltd), GeneFirst Limited, Meridian, Merck KGaA, SOPHiA GENETICS, Azenta U.S. Inc., CD Genomics, Twist Bioscience, PerkinElmer Genomics (A Subsidiary of PerkinElmer Inc.), GeneDx, LLC, Psomagen, and Integrated DNA Technologies, Inc.

Market Definition

Whole exome is a genomic technique for sequencing all of the protein-coding region of genes in a genome. Whole exome sequencing (WES) is available to patients who are searching for a unifying diagnosis for multiple medical conditions. A laboratory process that is used to determine the nucleotide sequence primarily of the exonic (or protein-coding) regions of an individual’s genome and related sequences, representing approximately 1% of the complete DNA sequence, called WES. Whole-exome sequencing is a widely used whole exome sequencing (WES) method that involves sequencing the protein-coding regions of the genome. The human exome represents less than 2% of the genome, but contains ~85% of known disease-related variants, 1 making this method a cost-effective alternative to whole-genome sequencing

North America Whole Exome Sequencing Market Dynamics

Drivers

  • Increasing Diagnostics Applications of Whole Exome Sequencing

There are over 7,000 identified rare diseases and approximately 80% are linked to genetic causes, diagnosing rare disease patients can often be challenging – resulting in lengthy, expensive, and emotional diagnostic odysseys.

Hence, diagnostic applications of WES is expected to propel the market size and is expected to act as driver for the global whole exome sequencing market in the forecast period.

  • Growing Usage of Targeted Sequencing Methods

Next-generation sequencing (NGS) is evolving as a powerful tool for providing a deeper and more precise insight at molecular underpinnings of individual tumours and specific receptors as genomics-focused pharmacology continues to play a greater role in the treatment of various chronic diseases especially cancer.

NGS offers advantages in accuracy, sensitivity and speed compared to traditional methods that have the potential to make a significant impact on the field of oncology. The need to order multiple tests to identify the causative mutation is eliminated because NGS can assess multiple genes in a single assay.

North America Whole Exome Sequencing Market

Opportunity

  • Increasing Product Launch in Recent Years

Market players are focusing on launch of new products in whole exome sequencing due to increasing demand for whole exome sequencing techniques. Advancement in the technology is helping the market players for multiple launches of products.

The product launches in the recent years have shown the potential of this technologies and the companies working on this market are trying to get more advanced product in the market which will act as opportunity for the market and will propel the market in forecast period.

Challenges/ Restraints

  • Cyber Security Concern in Genomics

Software is known to contain vulnerabilities caused by imperfect code, misconfiguration among other and NGS-related software, used to operate sequencing and laboratory equipment or carry out the bioinformatics analyses, is no exception. Software vulnerabilities are exploited to gain unauthorised access to computer systems or networks, leak data, crash or otherwise disrupt various services.

These types of incidences about data breach and cyber threat associated with the whole exome sequencing is expected to impede the market growth in the forecast period.

  • Lack of skilled professionals

The interpretation of whole-exome sequencing (WES) data requires expertise in genomic informatics and clinical medicine to ensure the accurate and safe reporting of findings. The first step of WES involves the acquisition of high-quality genomic DNA (gDNA) from biological samples, most commonly extracted from peripheral blood leukocytes. Professionals should have information about extraction of gDNA. In addition, the preparation of an exome enrichment library is required in WES which is not known to many healthcare specialists.

The professionals are lacking skills are not suitable for performing whole exome sequencing as the diagnostic samples of patients are of keen importance. The need for skilled healthcare has increased. Thus, the lack of skilled professionals to perform whole exome sequencing acts as challenge for the growth of the market.

Recent Development

  • In March, Thermo Fisher Scientific launched the CE-IVD marked Ion Torrent Genexus Dx Integrated Sequencer, an automated, next-generation sequencing (NGS) platform that delivers results in a single day. It is designed for use in clinical laboratories, the fully validated system enables users to perform both diagnostic testing and clinical research on a single instrument. This has helped the company to make advancements in its product portfolio

North America Whole Exome Sequencing Scope and Market Size

North America whole exome sequencing market is segmented on the basis of component, product and service, application, end user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

Component

On the basis of component, the North America whole exome sequencing market is segmented into whole exome sequencing and third-generation sequencing.

Product And Services

  • Systems
  • Kits
  • Services

On the basis of product and service, the North America whole exome sequencing market is segmented into systems, kits, and services.

Application

  • Diagnostics
  • Drug Discovery and Development
  • Personalized Medicine
  • Agriculture & Animal Research
  • Others

On the basis of application, the North America whole exome sequencing market is segmented into drug discovery and development, agriculture & animal research, diagnostics, personalized medicine, and others.

End User

  • Hospitals & Clinics
  • Pharmaceutical & Biotechnology Companies
  • Academic & Research Institutes
  • Clinical Laboratories
  • Others

On the basis of end user, the North America whole exome sequencing market is segmented into pharmaceutical & biotechnology companies, academic & research institutes, hospitals, clinical laboratories and others.

Distribution Channel

  • Direct Trade
  • Retail sales
  • Others

On the basis of distribution channel, the North America n whole exome sequencing (WES) market is segmented into direct trade, retail sales, and others.

Whole Exome Sequencing Market

North America Whole Exome Sequencing Market Regional Level Analysis

The whole exome sequencing market is analyzed and market size information is provided by component, product and service, application, end user, and distribution channel.

The countries covered in the whole exome sequencing (WES) market report are the U.S., Canada, Mexico.

U.S. is expected to dominate the market due to the presence of key market players along the largest consumer market with high GDP. U.S. is expected to grow due to rise in technological advancement.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of regional brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Competitive Landscape and North America Whole Exome Sequencing Market Share Analysis

Whole exome sequencing market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breath, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to the market.

Some of the major companies which are dealing in the North America whole exome sequencing market are Thermo Fisher Scientific Inc., QIAGEN, Illumina, Inc., Beckman Coulter, Inc., Eurofins Scientific, BIONEER CORPORATION, ExoDx (a part of Bio-Techne), FOUNDATION MEDICINE, INC. (A subsidiary of  F. Hoffmann-La Roche Ltd), GeneFirst Limited, CeGaT GmbH, Meridian, Merck KGaA, SOPHiA GENETICS, Azenta U.S. Inc.,  CD Genomics, Twist Bioscience, PerkinElmer Genomics (A Subsidiary of PerkinElmer Inc.), GeneDx, LLC, Psomagen, and Integrated DNA Technologies, Inc.,  among others.


SKU-

Get online access to the report on the World's First Market Intelligence Cloud

  • Interactive Data Analysis Dashboard
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
  • Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Request for Demo

Table of Content

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF NORTH AMERICA WHOLE EXOME SEQUENCING (WES) MARKET

1.4 CURRENCY AND PRICING

1.5 LIMITATIONS

1.6 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 DBMR TRIPOD DATA VALIDATION MODEL

2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.6 MULTIVARIATE MODELLING

2.7 MARKET APPLICATION COVERAGE GRID

2.8 PRODUCT TYPE LIFELINE CURVE

2.9 DBMR MARKET POSITION GRID

2.1 SECONDARY SOURCES

2.11 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHT

4.1 PORTER’S FIVE FORCES

4.2 PESTEL ANALYSIS

4.3 INDUSTRIAL INSIGHTS:

4.4 CONCLUSION

5 NORTH AMERICA WHOLE EXOME SEQUENCING MARKET: REGULATIONS

6 MARKET OVERVIEW

6.1 DRIVERS

6.1.1 GROWING USAGE OF TARGETED SEQUENCING METHODS

6.1.2 INCREASE IN THE ADOPTION OF NEXT GENERATION SEQUENCING

6.1.3 INCREASING DIAGNOSTICS APPLICATIONS OF WHOLE EXOME SEQUENCING

6.1.4 INCREASE TREND TOWARD PERSONALIZED MEDICATION

6.2 RESTRAINTS

6.2.1 LESS COMPREHENSIVE COVERAGE OF EXONS

6.2.2 CYBER SECURITY CONCERNS IN GENOMICS

6.3 OPPORTUNITIES

6.3.1 STRATEGIC INITIATIVES BY THE KEY MARKET PLAYER

6.3.2 INCREASING PRODUCT LAUNCHES IN RECENT YEARS

6.4 CHALLENGES

6.4.1 LACK OF SKILLED PROFESSIONALS

6.4.2 ETHICAL AND LEGAL ISSUES RELATED TO WHOLE EXOME SEQUENCING

7 NORTH AMERICA WHOLE EXOME SEQUENCING MARKET, BY COMPONENT

7.1 OVERVIEW

7.2 SECOND-GENERATION SEQUENCING

7.2.1 SEQUENCING BY SYNTHESIS (SBS)

7.2.2 SEQUENCING BY HYBRIDIZATION (SBH) AND SEQUENCING BY LIGATION (SBL)

7.3 THIRD-GENERATION SEQUENCING

8 NORTH AMERICA WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE

8.1 OVERVIEW

8.2 SYSTEMS

8.2.1 HISEQ SERIES

8.2.1.1 HISEQ 2500

8.2.1.2 HISEQ 1500

8.2.2 MISEQ SERIES

8.2.3 ION TORRENT PLATFORMS

8.2.3.1 ION PROTON

8.2.3.2 ION PGM

8.2.4 OTHERS

8.3 KITS

8.3.1 DNA FRAGMENTATION, END REPAIR, A-TAILING, AND SIZE SELECTION KITS

8.3.2 LIBRARY PREPARATION KITS

8.3.3 TARGET ENRICHMENT KITS

8.3.4 OTHERS

8.4 SERVICES

8.4.1 SEQUENCING SERVICES

8.4.2 DATA ANALYSIS (BIOINFORMATICS) SERVICES

8.4.3 OTHERS

9 NORTH AMERICA WHOLE EXOME SEQUENCING MARKET, BY APPLICATION

9.1 OVERVIEW

9.2 DRUG DISCOVERY AND DEVELOPMENT

9.3 AGRICULTURE & ANIMAL RESEARCH

9.4 DIAGNOSTICS

9.5 PERSONALIZED MEDICINE

9.6 OTHERS

10 NORTH AMERICA WHOLE EXOME SEQUENCING MARKET, BY END USER

10.1 OVERVIEW

10.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES

10.3 ACADEMIC & RESEARCH INSTITUTES

10.4 HOSPITALS AND CLINICS

10.5 CLINICAL LABORATORIES

10.6 OTHERS

11 NORTH AMERICA WHOLE EXOME SEQUENCING MARKET, BY DISTRIBUTION CHANNEL

11.1 OVERVIEW

11.2 DIRECT TRADE

11.3 RETAIL SALES

11.4 OTHERS

12 NORTH AMERICA WHOLE EXOME SEQUENCING MARKET, BY REGION

12.1 NORTH AMERICA

12.1.1 U.S.

12.1.2 CANADA

12.1.3 MEXICO

13 NORTH AMERICA WHOLE EXOME SEQUENCING MARKET: COMPANY LANDSCAPE

13.1 COMPANY SHARE ANALYSIS: NORTH AMERICA

14 COMPANY PROFILE

14.1 PERKINELMER GENOMICS (A SUBSIDIARY OF PERKINELMER INC.)

14.1.1 COMPANY SNAPSHOT

14.1.2 PRODUCT PORTFOLIO

14.1.3 RECENT DEVELOPMENTS

14.2 MERCK KGAA

14.2.1 COMPANY SNAPSHOT

14.2.2 REVENUE ANALYSIS

14.2.3 PRODUCT PORTFOLIO

14.2.4 RECENT DEVELOPMENTS

14.3 EXODX (A PART OF BIO-TECHNE)

14.3.1 COMPANY SNAPSHOT

14.3.2 PRODUCT PORTFOLIO

14.3.3 RECENT DEVELOPMENTS

14.4 THERMO FISHER SCIENTIFIC INC.

14.4.1 COMPANY SNAPSHOT

14.4.2 REVENUE ANALYSIS

14.4.3 PRODUCT PORTFOLIO

14.4.4 RECENT DEVELOPMENTS

14.5 FOUNDATION MEDICINE, INC. (A SUBSIDIARY OF F. HOFFMANN-LA ROCHE LTD)

14.5.1 COMPANY SNAPSHOT

14.5.2 PRODUCT PORTFOLIO

14.5.3 RECENT DEVELOPMENTS

14.6 AZENTA US, INC.

14.6.1 COMPANY SNAPSHOT

14.6.2 PRODUCT PORTFOLIO

14.6.3 RECENT DEVELOPMENTS

14.7 BECKMAN COULTER, INC

14.7.1 COMPANY SNAPSHOT

14.7.2 PRODUCT PORTFOLIO

14.7.3 RECENT DEVELOPMENTS

14.8 CD GENOMICS

14.8.1 COMPANY SNAPSHOT

14.8.2 PRODUCT PORTFOLIO

14.8.3 RECENT DEVELOPMENTS

14.9 EUROFINS SCIENTIFIC

14.9.1 COMPANY SNAPSHOT

14.9.2 REVENUE ANALYSIS

14.9.3 PRODUCT PORTFOLIO

14.9.4 RECENT DEVELOPMENTS

14.1 GENEDX, LLC

14.10.1 COMPANY SNAPSHOT

14.10.2 PRODUCT PORTFOLIO

14.10.3 RECENT DEVELOPMENTS

14.11 GENEFIRST LIMITED.

14.11.1 COMPANY SNAPSHOT

14.11.2 PRODUCT PORTFOLIO

14.11.3 RECENT DEVELOPMENTS

14.12 ILLUMINA, INC

14.12.1 COMPANY SNAPSHOT

14.12.2 REVENUE ANALYSIS

14.12.3 PRODUCT PORTFOLIO

14.12.4 RECENT DEVELOPMENTS

14.13 INTEGRATED DNA TECHNOLOGIES, INC.

14.13.1 COMPANY SNAPSHOT

14.13.2 PRODUCT PORTFOLIO

14.13.3 RECENT DEVELOPMENTS

14.14 MERIDIAN BIOSCIENCE, INC.

14.14.1 COMPANY SNAPSHOT

14.14.2 REVENUE ANALYSIS

14.14.3 PRODUCT PORTFOLIO

14.14.4 RECENT DEVELOPMENTS

14.15 PSOMAGEN

14.15.1 COMPANY SNAPSHOT

14.15.2 REVENUE ANALYSIS

14.15.3 PRODUCT PORTFOLIO

14.15.4 RECENT DEVELOPMENTS

14.16 QIAGEN

14.16.1 COMPANY SNAPSHOT

14.16.2 REVENUE ANALYSIS

14.16.3 PRODUCT PORTFOLIO

14.16.4 RECENT DEVELOPMENTS

14.17 SOPHIA GENETICS

14.17.1 COMPANY SNAPSHOT

14.17.2 REVENUE ANALYSIS

14.17.3 PRODUCT PORTFOLIO

14.17.4 RECENT DEVELOPMENTS

14.18 TWIST BIOSCIENCE

14.18.1 COMPANY SNAPSHOT

14.18.2 REVENUE ANALYSIS

14.18.3 PRODUCT PORTFOLIO

14.18.4 RECENT DEVELOPMENTS

15 QUESTIONNAIRE

16 RELATED REPORTS

List of Table

TABLE 1 NORTH AMERICA WHOLE EXOME SEQUENCING MARKET, BY COMPONENT, 2021- 2030 (USD MILLION)

TABLE 2 NORTH AMERICA SECOND-GENERATION SEQUENCING IN WHOLE EXOME SEQUENCING MARKET, BY COMPONENT, 2021- 2030 (USD MILLION)

TABLE 3 NORTH AMERICA WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2021- 2030 (USD MILLION)

TABLE 4 GLOBAL SYSTEMS IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2021- 2030 (USD MILLION)

TABLE 5 GLOBAL HISEQ SERIES IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2021- 2030 (USD MILLION)

TABLE 6 NORTH AMERICA ION TORRENT PLATFORMS IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2021- 2030 (USD MILLION)

TABLE 7 NORTH AMERICA KITS IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2021- 2030 (USD MILLION)

TABLE 8 NORTH AMERICA SERVICES IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2021- 2030 (USD MILLION)

TABLE 9 NORTH AMERICA WHOLE EXOME SEQUENCING MARKET, BY APPLICATION, 2021- 2030 (USD MILLION)

TABLE 10 NORTH AMERICA WHOLE EXOME SEQUENCING MARKET, BY END USER, 2021- 2030 (USD MILLION)

TABLE 11 NORTH AMERICA WHOLE EXOME SEQUENCING MARKET, BY DISTRIBUTION CHANNEL, 2021- 2030 (USD MILLION)

TABLE 12 U.S. WHOLE EXOME SEQUENCING MARKET, BY COMPONENT, 2021- 2030 (USD MILLION)

TABLE 13 U.S. SECOND-GENERATION SEQUENCING IN WHOLE EXOME SEQUENCING MARKET, BY COMPONENT, 2021- 2030 (USD MILLION)

TABLE 14 U.S. WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2021- 2030 (USD MILLION)

TABLE 15 U.S. SYSTEMS IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2021- 2030 (USD MILLION)

TABLE 16 U.S. HISEQ SERIES IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2021- 2030 (USD MILLION)

TABLE 17 U.S. ION TORRENT PLATFORMS IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2021- 2030 (USD MILLION)

TABLE 18 U.S. KITS IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2021- 2030 (USD MILLION)

TABLE 19 U.S. SERVICES IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2021- 2030 (USD MILLION)

TABLE 20 U.S. WHOLE EXOME SEQUENCING MARKET, BY APPLICATION, 2021- 2030 (USD MILLION)

TABLE 21 U.S. WHOLE EXOME SEQUENCING MARKET, BY END USER, 2021- 2030 (USD MILLION)

TABLE 22 U.S. WHOLE EXOME SEQUENCING MARKET, BY DISTRIBUTION CHANNEL, 2021- 2030 (USD MILLION)

TABLE 23 CANADA WHOLE EXOME SEQUENCING MARKET, BY COMPONENT, 2021- 2030 (USD MILLION)

TABLE 24 CANADA SECOND-GENERATION SEQUENCING IN WHOLE EXOME SEQUENCING MARKET, BY COMPONENT, 2021- 2030 (USD MILLION)

TABLE 25 CANADA WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2021- 2030 (USD MILLION)

TABLE 26 CANADA SYSTEMS IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2021- 2030 (USD MILLION)

TABLE 27 CANADA HISEQ SERIES IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2021- 2030 (USD MILLION)

TABLE 28 CANADA ION TORRENT PLATFORMS IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2021- 2030 (USD MILLION)

TABLE 29 CANADA KITS IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2021- 2030 (USD MILLION)

TABLE 30 CANADA SERVICES IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2021- 2030 (USD MILLION)

TABLE 31 CANADA WHOLE EXOME SEQUENCING MARKET, BY APPLICATION, 2021- 2030 (USD MILLION)

TABLE 32 CANADA WHOLE EXOME SEQUENCING MARKET, BY END USER, 2021- 2030 (USD MILLION)

TABLE 33 CANADA WHOLE EXOME SEQUENCING MARKET, BY DISTRIBUTION CHANNEL, 2021- 2030 (USD MILLION)

TABLE 34 MEXICO WHOLE EXOME SEQUENCING MARKET, BY COMPONENT, 2021- 2030 (USD MILLION)

TABLE 35 MEXICO SECOND-GENERATION SEQUENCING IN WHOLE EXOME SEQUENCING MARKET, BY COMPONENT, 2021- 2030 (USD MILLION)

TABLE 36 MEXICO WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2021- 2030 (USD MILLION)

TABLE 37 MEXICO SYSTEMS IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2021- 2030 (USD MILLION)

TABLE 38 MEXICO HISEQ SERIES IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2021- 2030 (USD MILLION)

TABLE 39 MEXICO ION TORRENT PLATFORMS IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2021- 2030 (USD MILLION)

TABLE 40 MEXICO KITS IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2021- 2030 (USD MILLION)

TABLE 41 MEXICO SERVICES IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2021- 2030 (USD MILLION)

TABLE 42 MEXICO WHOLE EXOME SEQUENCING MARKET, BY APPLICATION, 2021- 2030 (USD MILLION)

TABLE 43 MEXICO WHOLE EXOME SEQUENCING MARKET, BY END USER, 2021- 2030 (USD MILLION)

TABLE 44 MEXICO WHOLE EXOME SEQUENCING MARKET, BY DISTRIBUTION CHANNEL, 2021- 2030 (USD MILLION)

List of Figure

FIGURE 1 NORTH AMERICA WHOLE EXOME SEQUENCING (WES) MARKET: SEGMENTATION

FIGURE 2 NORTH AMERICA WHOLE EXOME SEQUENCING (WES) MARKET: DATA TRIANGULATION

FIGURE 3 NORTH AMERICA WHOLE EXOME SEQUENCING (WES) MARKET: DROC ANALYSIS

FIGURE 4 NORTH AMERICA WHOLE EXOME SEQUENCING (WES) MARKET: REGIONAL VS COUNTRY MARKET ANALYSIS

FIGURE 5 NORTH AMERICA WHOLE EXOME SEQUENCING (WES) MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 NORTH AMERICA WHOLE EXOME SEQUENCING (WES) MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 NORTH AMERICA WHOLE EXOME SEQUENCING (WES) MARKET: MARKET APPLICATION COVERAGE GRID

FIGURE 8 NORTH AMERICA WHOLE EXOME SEQUENCING (WES) MARKET: DBMR MARKET POSITION GRID

FIGURE 9 NORTH AMERICA WHOLE EXOME SEQUENCING (WES) MARKET: SEGMENTATION

FIGURE 10 INCREASE IN USE OF WES TECHNOLOGY FOR NEW SCIENTIFIC APPLICATIONS AND INCREASING THE PREFERENCE OF WES OVER WHOLE-GENOME SEQUENCING IS ITS LOW-COST SEQUENCING CAPABILITY IS EXPECTED TO DRIVE THE NORTH AMERICA WHOLE EXOME SEQUENCING (WES) MARKET IN THE FORECAST PERIOD OF 2023 TO 2030

FIGURE 11 THE COMPONENT SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA WHOLE EXOME SEQUENCING (WES) MARKET IN 2023 & 2030

FIGURE 12 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF THE NORTH AMERICA WHOLE EXOME SEQUENCING MARKET

FIGURE 13 NORTH AMERICA WHOLE EXOME SEQUENCING MARKET: BY COMPONENT, 2022

FIGURE 14 NORTH AMERICA WHOLE EXOME SEQUENCING MARKET: BY COMPONENT, 2022-2029 (USD MILLION)

FIGURE 15 NORTH AMERICA WHOLE EXOME SEQUENCING MARKET: BY COMPONENT, CAGR (2022-2029)

FIGURE 16 NORTH AMERICA WHOLE EXOME SEQUENCING MARKET: BY COMPONENT, LIFELINE CURVE

FIGURE 17 NORTH AMERICA WHOLE EXOME SEQUENCING MARKET: BY PRODUCT AND SERVICE, 2022

FIGURE 18 NORTH AMERICA WHOLE EXOME SEQUENCING MARKET: BY PRODUCT AND SERVICE, 2023-2030 (USD MILLION)

FIGURE 19 NORTH AMERICA WHOLE EXOME SEQUENCING MARKET: BY PRODUCT AND SERVICE, CAGR (2023-2030)

FIGURE 20 NORTH AMERICA WHOLE EXOME SEQUENCING MARKET: BY PRODUCT AND SERVICE, LIFELINE CURVE

FIGURE 21 NORTH AMERICA WHOLE EXOME SEQUENCING MARKET: BY APPLICATION, 2022

FIGURE 22 NORTH AMERICA WHOLE EXOME SEQUENCING MARKET: BY APPLICATION, 2023-2030 (USD MILLION)

FIGURE 23 NORTH AMERICA WHOLE EXOME SEQUENCING MARKET: BY APPLICATION, CAGR (2023-2030)

FIGURE 24 NORTH AMERICA WHOLE EXOME SEQUENCING MARKET: BY APPLICATION, LIFELINE CURVE

FIGURE 25 NORTH AMERICA WHOLE EXOME SEQUENCING MARKET: BY END USER, 2022

FIGURE 26 NORTH AMERICA WHOLE EXOME SEQUENCING MARKET: BY END USER, 2023-2030 (USD MILLION)

FIGURE 27 NORTH AMERICA WHOLE EXOME SEQUENCING MARKET: BY END USER, CAGR (2023-2030)

FIGURE 28 NORTH AMERICA WHOLE EXOME SEQUENCING MARKET: BY END USER, LIFELINE CURVE

FIGURE 29 NORTH AMERICA WHOLE EXOME SEQUENCING MARKET: BY DISTRIBUTION CHANNEL, 2022

FIGURE 30 NORTH AMERICA WHOLE EXOME SEQUENCING MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)

FIGURE 31 NORTH AMERICA WHOLE EXOME SEQUENCING MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)

FIGURE 32 NORTH AMERICA WHOLE EXOME SEQUENCING MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 33 NORTH AMERICA WHOLE EXOME SEQUENCING MARKET: SNAPSHOT (2022)

FIGURE 34 NORTH AMERICA WHOLE EXOME SEQUENCING MARKET: BY COUNTRY (2022)

FIGURE 35 NORTH AMERICA WHOLE EXOME SEQUENCING MARKET: BY COUNTRY (2023 & 2030)

FIGURE 36 NORTH AMERICA WHOLE EXOME SEQUENCING MARKET: BY COUNTRY (2022 & 2030)

FIGURE 37 NORTH AMERICA WHOLE EXOME SEQUENCING MARKET: BY COMPONENT (2023-2030)

FIGURE 38 NORTH AMERICA WHOLE EXOME SEQUENCING MARKET: COMPANY SHARE 2022 (%)

View Detailed Information Right Arrow

Research Methodology

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Customization Available

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Frequently Asked Questions

North America Whole Exome Sequencing Market will be worth USD 2,192.73 million by 2030.
North America Whole Exome Sequencing Market growth rate is 22.0% during the forecast period.
Increasing Diagnostics Applications of Whole Exome Sequencing and Growing Usage of Targeted Sequencing Methods are the growth drivers of the North America Whole Exome Sequencing Market.
Component, product and service, application, end-user, and distribution channel are the factors on which the North America Whole Exome Sequencing Market research is based.
Thermo Fisher Scientific launched the CE-IVD marked Ion Torrent Genexus Dx Integrated Sequencer, an automated, next-generation sequencing (NGS) platform that delivers results in a single day and It is designed for use in clinical laboratories, the fully validated system enables users to perform both diagnostic testing and clinical research on a single instrument are the latest developments in the North America Whole Exome Sequencing Market.